Sanofi Pasteur is the vaccines division of the multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines.
Sanofi Pasteur is one of four global producers of the yellow fever vaccine.
Maps, Directions, and Place Reviews
History
In 2004, Aventis merged with and into Sanofi. The new Sanofi-Aventis Group became the world's 3rd largest pharmaceutical company. Aventis Pasteur, the vaccine division of Sanofi-Aventis Group, changed its name to Sanofi Pasteur. In 2014, Sanofi Pasteur stopped producing its effective Fav-Afrique antivenom because competition from cheaper though less powerful competitors made it unprofitable. Doctors Without Borders said that it would take two years to develop a similar antivenom, and that existing stocks would run out in June 2016.
Key dates
- 1897: Marcel Mérieux creates the Mérieux Biological Institute in Lyon. Richard Slee creates the Pocono Biological Laboratories, in Swiftwater, Pennsylvania in the U.S.
- 1914: John G. FitzGerald creates Connaught Laboratories, part of the University of Toronto.
- 1968: Rhône-Poulenc acquires 51% of the capital of the Institut Mérieux.
- 1974: Pasteur Institute creates Pasteur Production, a subsidiary specializing in manufacturing vaccines.
- 1978: Connaught Laboratories in Canada acquires the vaccine manufacturing facility (Merrell-National Laboratories) at Swiftwater, Pennsylvania, U.S.
- 1985: Pasteur Production is acquired by the Mérieux Institute, and Pasteur Vaccins is created.
- 1989: The Mérieux Institute acquires the Connaught Laboratories in Canada and its subsidiaries and becomes a world leader in human biology.
- 1990: Creation of Pasteur Mérieux Serums & Vaccins.
- 1994: Pasteur Mérieux Sérums & Vaccins becomes a wholly owned subsidiary of Rhône-Poulenc.
- 1996: Pasteur Mérieux Connaught is the new name of Pasteur Mérieux Serums et Vaccins.
- 1999: Rhône-Poulenc and Hoechst unite their Life Sciences activities in a single company, which takes on the name Aventis. Within this group, Pasteur Mérieux Connaught changes its name to Aventis Pasteur.
- 2004: merger of Aventis with and into Sanofi. The new Sanofi-Aventis Group becomes the world's 3rd largest pharmaceutical company, behind Pfizer and GlaxoSmithKline. Aventis Pasteur, the vaccine division of the Sanofi-Aventis Group, changes its name to Sanofi Pasteur.
- 2008: Sanofi Pasteur acquires Acambis plc, a biotech company.
- 2009: Sanofi Pasteur acquires major stake in Hyderabad-based Shantha Biotechnics.
Yellow Fever Vaccine Pharmacy Video
Key facts & figures in 2012
Sanofi Pasteur
- 2012 net sales: EUR3,897 millions (+5.7% over 2011)
- Staff: nearly 13,000 employees worldwide
- More than 1 billion doses of vaccines produced yearly to immunize more than 500 million people in the world
- Largest product range available, against 20 infectious diseases
- More than EUR1 million invested every day in R&D
- Nearly EUR2 billion invested in the last 5 years in production infrastructures.
- Headquarters: Lyon, France
- 14 production and/or R&D sites located in:
- Marcy-l'Étoile and Val-de-Reuil, France
- Swiftwater, Pennsylvania (Sanofi Pasteur's United States headquarters), Cambridge, Massachusetts and Canton, Massachusetts, Orlando, Florida and Rockville, Maryland, United States
- Toronto, Ontario, Canada
- Pilar, Buenos Aires Province, Argentina
- Shenzhen, China
- Hyderabad, India
- Ocoyoacac, Mexico
- Chachoengsao, Thailand
- Neuville-sur-Saône, France
Vaccines
the listing below is for named vaccines; Sanofi Pasteur produces many vaccines which do not bear trade names
- Cancer vaccines
- bladder cancer: TheraCys
- Chickenpox vaccines
- Varivax
- Dengue vaccines
- Dengvaxia, approved in 18 countries
- DPT vaccines
- Adacel
- DAPTACEL
- Tripedia (Trepedia)
- Haemophilus influenzae type b vaccines
- ActHIB
- ACT-HIB
- Hepatitis A vaccines
- Avaxim 160 U (or just Avaxim)
- Hepatitis B vaccines
- Genhevac B Pasteur
- Hbvaxpro (5, 10 and 40 ?g)
- Human Papilloma Virus vaccines
- Gardasil
- Influenza vaccines
- Addigrip
- Fluzone (standard; without preservatives; pediatric dose without preservatives)
- Sandovac
- Vaxigrip
- Japanese encephalitis virus vaccines
- JE-VAX
- Measles vaccines
- Rouvax
- Meningococcal vaccines
- Menactra, the first meningococcal vaccine approved for use in infants
- Menomune-A/C/Y/W-135
- Vaccin Meningococcique A+C
- MMR vaccines
- M-M-Rvaxpro
- Pneumonia vaccines
- Pneumo 23
- Polio vaccines
- Imovax Polio
- IPOL
- Polio Salk
- Rabies vaccines
- IMOVAX RABIES (Imovax)
- Imogam Rabies-HT, rabies immune globulin
- Vaccin Rabique Pasteur
- Rotavirus vaccines
- Rotateq
- Rubella vaccines
- Rudivax
- Smallpox vaccines
- ACAM 2000
- Tetanus vaccines
- Vaccin Tetanique Pasteur
- Tuberculosis vaccines
- Mycobax
- Tubersol
- Vaccin Bcg Ssi
- Typhoid fever vaccines
- Typhim Vi
- Yellow fever vaccines
- Stamaril
- YF-VAX
- Zoster vaccines (shingles)
- Zostavax
- Diphtheria and tetanus combined vaccines
- DECAVAC
- dT reduct
- D. T. Vax
- Diphtheria, tetanus and polio combined vaccines
- Revaxis
- DPT, haemophilus combined vaccines
- TriHIBit, a booster vaccine, with DPT and haemophilus influenzae type b vaccines
- DPT, polio combined vaccines
- Repevax
- DPT, haemophilus, polio combined vaccines
- Pentacel
- Pentavac
- DPT, haemophilus, polio, hepatitis B combined vaccines
- Hexavac
- Hepatitis A, typhoid fever combined vaccines
- Tyavax
2012 BCG supply shortage
In the fall of 2011 the Sanofi Pasteur plant flooded causing problems with mold. The facility, located in Toronto, Ontario, Canada, produced BCG vaccine products, made with the Glaxo 1077 strain, such as a tuberculosis vaccine ImmuCYST, a BCG immunotherapeutic, a bladder cancer drug. By April 2012 the FDA had found dozens of documented problems with sterility at the plant including mold, nesting birds and rusted electrical conduits. The resulting closure of the plant for over two years resulting in shortages of bladder cancer and tuberculosis vaccines. On October 29, 2014 Health Canada gave the permission for Sanofi to resume production of BCG.
Sanofi Biogenius Canada
Sanofi Pasteur is the founding sponsor of Sanofi Biogenius Canada (SBC), a national, biotechnology-focused science competition for Canadian high school and CEGEP students. Those selected for the SBC work with local mentors, giving students hands-on research experience in a professional lab setting. Participants compile their results and present their findings at regional competitions. Cash prizes are awarded and regional winners advance to the National stage, where they vie for the top spot and the chance to compete in the International BioGENEius Challenge, held at the prestigious BIO International Convention - the largest biotechnology event in the world.
Source of the article : Wikipedia
EmoticonEmoticon